|
1
|
Shepard CW, Finelli L and Alter MJ: Global
epidemiology of hepatitis C virus infection. Lancet Infect Dis.
5:558–567. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Manns MP, Wedemeyer H and Cornberg M:
Treating viral hepatitis C: efficacy, side effects, and
complications. Gut. 55:1350–1359. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Moreno C and Deltenre P: Management of
chronic hepatitis C in 2012 in Belgium. Rev Med Brux. 33:223–227.
2012.(In French).
|
|
4
|
Yu CI and Chiang BL: A new insight into
hepatitis C vaccine development. J Biomed Biotechnol.
2010:5482802010.PubMed/NCBI
|
|
5
|
Tang HL and Grisé H: Cellular and
molecular biology of HCV infection and hepatitis. Clin Sci (Lond).
117:49–65. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Stoll-Keller F, Barth H, Fafi-Kremer S,
Zeisel MB and Baumert TF: Development of hepatitis C virus
vaccines: challenges and progress. Expert Rev Vaccines. 8:333–345.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dazert E, Neumann-Haefelin C, Bressanelli
S, Fitzmaurice K, Kort J, Timm J, McKiernan S, Kelleher D, Gruener
N, Tavis JE, Rosen HR, Shaw J, Bowness P, Blum HE, Klenerman P,
Bartenschlager R and Thimme R: Loss of viral fitness and
cross-recognition by CD8+ T cells limit HCV escape from
a protective HLA-B27-restricted human immune response. J Clin
Invest. 119:376–386. 2009.PubMed/NCBI
|
|
8
|
Bain C, Fatmi A, Zoulim F, Zarski JP,
Trépo C and Inchauspé G: Impaired allostimulatory function of
dendritic cells in chronic hepatitis C infection. Gastroenterology.
120:512–524. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ciesek S, Liermann H, Hadem J, Greten T,
Tillmann HL, Cornberg M, Aslan N, Manns MP and Wedemeyer H:
Impaired TRAIL-dependent cytotoxicity of CD1c positive dendritic
cells in chronic hepatitis C virus infection. J Viral Hepat.
15:200–211. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wedemeyer H, He XS, Nascimbeni M, Davis
AR, Greenberg HB, Hoofnagle JH, Liang TJ, Alter H and Rehermann B:
Impaired effector function of hepatitis C virus specific
CD8+ T cells in chronic hepatitis C virus infection. J
Immunol. 169:3447–3458. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Steinman RM and Banchereau J: Taking
dendritic cells into medicine. Nature. 449:419–426. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tuyaerts S, Aerts JL, Corthals J, Neyns B,
Heirman C, Breckpot K, Thielemans K and Bonehill A: Current
approaches in dendritic cell generation and future implications for
cancer immunotherapy. Cancer Immunol Immunother. 56:1513–1537.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lundqvist A, Noffz G, Pavlenko M,
Saebøe-Larssen S, Fong T, Maitland N and Pisa P: Nonviral and viral
gene transfer into different subsets of human dendritic cells yield
comparable efficiency of transfection. J Immunother. 25:445–454.
2002. View Article : Google Scholar
|
|
14
|
Dietz AB and Vuk Pavlovic S: High
efficiency adenovirus mediated gene transfer to human dendritic
cells. Blood. 91:392–398. 1998.PubMed/NCBI
|
|
15
|
Li D, Xie YW, Xue XP, Bai XF and Jia ZS:
Forecasting of hepatitis C virus CTL epitopes and design of
multi-epitopes vaccine. Zhonghua Gan Zang Bing Za Zhi. 17:786–787.
2009.(In Chinese).
|
|
16
|
Duan L, Lei P, Yumei X, Xiaoping X, Futao
Z, Li M, Xin W, Jiuping W, Xuefan B and Zhansheng J: Prediction and
identification of Chinese hepatitis C viral specific cytotoxic T
lymphocyte epitopes. J Med Virol. 83:1315–1320. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Diepolder HM, Gerlach JT, Zachoval R,
Hoffmann RM, Jung MC, Wierenga EA, Scholz S, Santantonio T,
Houghton M, Southwood S, Sette A and Pape GR: Immunodominant
CD4+ T-cell epitope within nonstructural protein 3 in
acute hepatitis C virus infection. J Virol. 71:6011–6019. 1997.
|
|
18
|
Wang QM, Sun SH, Hu ZL, Zhou FJ, Yin M,
Xiao CJ and Zhang JC: Epitope DNA vaccines against tuberculosis:
spacers and ubiquitin modulates cellular immune responses elicited
by epitope DNA vaccine. Scand J Immunol. 60:219–225. 2004.
View Article : Google Scholar
|
|
19
|
Cerny A, McHutchison JG, Pasquinelli C,
Brown ME, Brothers MA, Grabscheid B, Fowler P, Houghton M and
Chisari FV: Cytotoxic T lymphocyte response to hepatitis C
virus-derived peptides containing the HLA A2.1 binding motif. J
Clin Invest. 95:521–530. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Luo J, Deng ZL, Luo X, Tang N, Song WX,
Chen J, Sharff KA, Luu HH, Haydon RC, Kinzler KW, Vogelstein B and
He TC: A protocol for rapid generation of recombinant adenoviruses
using the AdEasy system. Nat Protoc. 2:1236–1247. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pham L, Ye H, Cosset FL, Russell SJ and
Peng KW: Concentration of viral vectors by co-precipitation with
calcium phosphate. J Gene Med. 3:188–194. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mittereder N, March KL and Trapnell BC:
Evaluation of the concentration and bioactivity of adenovirus
vectors for gene therapy. J Virol. 70:7498–7509. 1996.PubMed/NCBI
|
|
23
|
English D and Andersen BR: Single-step
separation of red blood cells. Granulocytes and mononuclear
leukocytes on discontinuous density gradients of Ficoll-Hypaque. J
Immunol Methods. 5:249–252. 1974. View Article : Google Scholar
|
|
24
|
Babatz J, Röllig C, Oelschlägel U, Zhao S,
Ehninger G, Schmitz M and Bornhäuser M: Large-scale immunomagnetic
selection of CD14+ monocytes to generate dendritic cells
for cancer immunotherapy: a phase I study. J Hematother Stem Cell
Res. 12:515–523. 2003.PubMed/NCBI
|
|
25
|
Timares L, Douglas JT, Tillman BW,
Krasnykh V and Curiel DT: Adenovirus-mediated gene delivery to
dendritic cells. Methods Mol Biol. 246:139–153. 2004.PubMed/NCBI
|
|
26
|
Wang L, Wang ZH, Shen CY, You ML, Xiao JF
and Chen GQ: Differentiation of human bone marrow mesenchymal stem
cells grown in terpolyesters of 3-hydroxyalkanoates scaffolds into
nerve cells. Biomaterials. 31:1691–1698. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ma L, Wei X, Zhang Y, Wang PZ, Lian JQ and
Jia ZS: Observation of chimeric hepatitis C virus in infected
Huh7.5 cell through transmission electron microscopy. Chin J
Microbiol Immunol. 29:568–573. 2009.
|
|
28
|
Lindenbach BD, Evans MJ, Syder AJ, Wölk B,
Tellinghuisen TL, Liu CC, Maruyama T, Hynes RO, Burton DR,
McKeating JA and Rice CM: Complete replication of hepatitis C virus
in cell culture. Science. 309:623–626. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Brand K, Klocke R, Possling A, Paul D and
Strauss M: Induction of apoptosis and G2/M arrest by infection with
replication-deficient adenovirus at high multiplicity of infection.
Gene Ther. 6:1054–1063. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Figdor CG, de Vries IJ, Lesterhuis WJ and
Melief CJ: Dendritic cell immunotherapy: mapping the way. Nat Med.
10:475–480. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Vorburger SA and Hunt KK: Adenoviral gene
therapy. Oncologist. 7:46–59. 2002. View Article : Google Scholar
|
|
32
|
Lasaro MO and Ertl HC: New insights on
adenovirus as vaccine vectors. Mol Ther. 17:1333–1339. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Liu J, Cao S, Kim S, Chung EY, Homma Y,
Guan X, Jimenez V and Ma X: Interleukin-12: an update on its
immunological activities, signaling and regulation of gene
expression. Curr Immunol Rev. 1:119–137. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gattoni A, Parlato A, Vangieri B,
Bresciani M and Derna R: Interferon-gamma: biologic functions and
HCV terapy (type I/II) (2 of 2 parts). Clin Ter. 157:457–468.
2006.PubMed/NCBI
|
|
35
|
Yanagi M, Purcell RH, Emerson SU and Bukh
J: Hepatitis C virus: an infectious molecular clone of a second
major genotype (2a) and lack of viability of intertypic 1a and 2a
chimeras. Virology. 262:250–263. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Thimme R, Bukh J, Spangenberg HC, Wieland
S, Pemberton J, Steiger C, Govindarajan S, Purcell RH and Chisari
FV: Viral and immunological determinants of hepatitis C virus
clearance, persistence, and disease. Proc Natl Acad Sci USA.
99:15661–15668. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Thimme R, Oldach D, Chang KM, Steiger C,
Ray SC and Chisari FV: Determinants of viral clearance and
persistence during acute hepatitis C virus infection. J Exp Med.
194:1395–1406. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Liu C, Zhu H, Tu Z, Xu YL and Nelson DR:
CD8+ T-cell interaction with HCV replicon cells:
evidence for both cytokine- and cell-mediated antiviral activity.
Hepatology. 37:1335–1342. 2003.
|
|
39
|
Jo J, Aichele U, Kersting N, Klein R,
Aichele P, Bisse E, Sewell AK, Blum HE, Bartenschlager R, Lohmann V
and Thimme R: Analysis of CD8+ T-cell-mediated
inhibition of hepatitis C virus replication using a novel
immunological model. Gastroenterology. 136:1391–1401. 2009.
|
|
40
|
Bowen DG and Walker CM: Adaptive immune
responses in acute and chronic hepatitis C virus infection. Nature.
436:946–952. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Frese M, Schwärzle V, Barth K, Krieger N,
Lohmann V, Mihm S, Haller O and Bartenschlager R: Interferon-gamma
inhibits replication of subgenomic and genomic hepatitis C virus
RNAs. Hepatology. 35:694–703. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Klade CS, Wedemeyer H, Berg T, Hinrichsen
H, Cholewinska G, Zeuzem S, Blum H, Buschle M, Jelovcan S, Buerger
V, Tauber E, Frisch J and Manns MP: Therapeutic vaccination of
chronic hepatitis C nonresponder patients with the peptide vaccine
IC41. Gastroenterology. 134:1385–1395. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Alvarez-Lajonchere L, Shoukry NH, Grá B,
Amador-Cañizares Y, Helle F, Bédard N, Guerra I, Drouin C,
Dubuisson J, González-Horta EE, Martínez G, Marante J, Cinza Z,
Castellanos M and Dueñas-Carrera S: Immunogenicity of CIGB-230, a
therapeutic DNA vaccine preparation, in HCV-chronically infected
individuals in a Phase I clinical trial. J Viral Hepat. 16:156–167.
2009. View Article : Google Scholar
|
|
44
|
Gowans EJ, Roberts S, Jones K, Dinatale I,
Latour PA, Chua B, Eriksson EM, Chin R, Li S, Wall DM, Sparrow RL,
Moloney J, Loudovaris M, Ffrench R, Prince HM, Hart D, Zeng W,
Torresi J, Brown LE and Jackson DC: A phase I clinical trial of
dendritic cell immunotherapy in HCV-infected individuals. J
Hepatol. 53:599–607. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhou Y, Zhang Y, Yao ZQ, Moorman JP and
Jia ZS: Dendritic cell-based immunity and vaccination against
hepatitis C virus infection. Immunology. 136:385–396. 2012.
View Article : Google Scholar : PubMed/NCBI
|
